05:15 PM EDT, 04/16/2024 (MT Newswires) -- ClearPoint Neuro ( CLPT ) said late Tuesday its partner AviadoBio treated the first patient in a phase 1/2 trial assessing AVB-101 to treat frontotemporal dementia with progranulin mutations potentially.

Trial sites in the US and EU are using ClearPoint's Navigation system and SmartFlow cannula for intrathalamic administration of the investigational gene therapy, the company said.